TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01454622
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT01298401
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04232813
Drug: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
Normalized name: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
Study: NCT02221037
Drug: GSK2862277
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Study: NCT02221037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Study: NCT04031612
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy
Study: NCT01618591
Drug: Single dose azithromycin 500 mg
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study: NCT01618591
Drug: Single dose azithromycin 1000 mg plus loperamide
Normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study: NCT01618591
Drug: Single dose azithromycin 1000 mg plus placebo
Normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
Study: NCT00391079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
Study: NCT00635284
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-rapamycin
Study: NCT00976092
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. bolus of 70-100 IU/kg body weight
Study: NCT01031966
Drug: Thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Study: NCT01031966
Drug: Thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Study: NCT03832699
Drug: Endometrin 100Mg Vaginal Insert
Normalized name: Endometrin 100mg Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Endometrin 100 mg twice daily
Study: NCT00352144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00508625
Drug: AMG 951 (rhApo2L/TRAIL)
Normalized name: Mane 'N Tail Mineral Ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
Study: NCT01816815
Drug: BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01816815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02796131
Drug: RDX5791
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02796131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02182869
Drug: Combivent® HFA inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182869
Drug: Combivent® CFC inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01492972
Drug: Androgen Suppression Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
Study: NCT00386126
Drug: Iron Sucrose IV 200mg, once a week, for 5 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03113448
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study: NCT01009671
Drug: ART 44
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01009671
Drug: ART 50
Normalized name: FLORASTART 500mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467259
Drug: Testosterone Transdermal System
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Study: NCT00467259
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch, changed twice a week for 52 weeks
Study: NCT04304807
Drug: Melatonin 20 mg
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
Study: NCT04304807
Drug: Traditional antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
Study: NCT00136318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00426010
Drug: caffeine/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine or placebo, either overt or covert
Study: NCT01227655
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will be used.
Study: NCT01227655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT01227655
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01150981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule daily for 6 weeks.
Study: NCT03185403
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02322398
Drug: rFSH plus rLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
Study: NCT01825122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322398
Drug: hMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-300 IU/d hMG
Study: NCT02139124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule
Study: NCT02139124
Drug: PRC-063 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg capsule - active
Study: NCT02139124
Drug: PRC-063 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 70 mg capsule - active
Study: NCT02139124
Drug: PRC-063 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 100 mg capsule - active
Study: NCT00352235
Drug: KRN7000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03854305
Drug: PRV-6527
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT03854305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT00251641
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
Study: NCT01348984
Drug: transdermal fentanyl patch
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TFP = transdermal fentanyl patch (50 microgram/hour)
Study: NCT01348984
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 2 = placebo patch
Study: NCT03253250
Drug: ETV；TDF；ADV
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAs
Study: NCT01981499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00772720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 7 days
Study: NCT03482167
Drug: Niagen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsules (4 capsules daily)
Study: NCT00864266
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
Study: NCT01949168
Drug: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01949168
Drug: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01949168
Drug: Rebetol® (ribavirin), 1000/1200mg by mouth daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02044549
Drug: Syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterotonins
Study: NCT04158336
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 is a study drug
Study: NCT00975286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT00621036
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02080832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 8 weeks
Study: NCT00043537
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00043537
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01674647
Drug: Vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
Study: NCT03697265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) adminstration
Study: NCT01490866
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 Days 1 and 15; IV
Study: NCT01524913
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc celestone (6 mg/cc) will be injected into the joint space
Study: NCT00005823
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03822364
Drug: 009-2
Normalized name: Flumist 2009-2010 Formula Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled apomorphine via Staccato aerosol, Dose 2
Study: NCT00195013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 grams three times a day (orally) for four days and then stop
Study: NCT01606059
Drug: DW-0920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Extended release tablet Dosage: 2 tablets
Study: NCT01606059
Drug: DW-0919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Extended release tablet Dosage: 1 tablet
Study: NCT02728752
Drug: Octagam 10%
Normalized name: Octagam 10% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be treated with Octagam 10%
Study: NCT01181271
Drug: Cyclophosphamide (conditioning for AUTO transplant)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
Study: NCT04744142
Drug: Ketone supplementation
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive either placebo or ketone ester supplementation
Study: NCT01181271
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
Study: NCT04054128
Drug: Heparin Sodium, 1000 Units/mL Injectable Solution 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
Study: NCT02182128
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04668976
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Please see Detailed Description.
Study: NCT04668976
Drug: Anti-EGFR (Panitumumab or Cetuximab)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Detailed Description.
Study: NCT01794975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01565265
Drug: Pergoveris in long protocol with GnRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
Study: NCT00869986
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, once every six months for 15 months
Study: NCT00378716
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00378716
Drug: uracil
Normalized name: uracil
DrugBank: Uracil (DB03419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04336124
Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur.
Study: NCT00695435
Drug: TOBRADEX Ophthalmic Suspension
Normalized name: Tobradex Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
Study: NCT00695435
Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
Study: NCT00695435
Drug: TOBREX Ophthalmic Solution
Normalized name: Tobrex Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBREX Ophthalmic Solution 1 drop each eye at baseline
Study: NCT00750308
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching ramipril
Study: NCT00750308
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tadalafil
Study: NCT02646449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Study: NCT00038610
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
Study: NCT00038610
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
Study: NCT00038610
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8.
Study: NCT03340870
Drug: Sonazoid™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
Study: NCT03864042
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: taken orally
Study: NCT03864042
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: taken orally
Study: NCT04455178
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
Study: NCT04455178
Drug: Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
Study: NCT01518166
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study: NCT01940497
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
Study: NCT02707861
Drug: Optimized Background Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Study: NCT02494102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02196740
Drug: Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste
Normalized name: ciprofloxacin and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulp removal,Root canal irrigation and disinfection,
Study: NCT00004135
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00116519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03639519
Drug: Ascorbic Acid 500Mg Chew Tab
Normalized name: ASCORBIC ACID 500MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbic acid will be administered at the night before surgery and will be continued for five days
Study: NCT00511667
Drug: MK0941
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Study: NCT00511667
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Study: NCT02489019
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
Study: NCT00448136
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m2/day iv on days 1-5 every 6 weeks
Study: NCT00554775
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
Study: NCT00266357
Drug: Placebo / Duration of Treatment: 2 days for screening period
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02987920
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional medication to perioperative analgesic regimen to Group A
Study: NCT02987920
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic regimen to Group A and Group B
Study: NCT03218163
Drug: MEDI-551 Maintenance
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
Study: NCT00004734
Drug: pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004734
Drug: folic acid multivitamin
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02299817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo